tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Nurix Therapeutics price target lowered to $30 from $32 at Oppenheimer
PremiumThe FlyNurix Therapeutics price target lowered to $30 from $32 at Oppenheimer
12d ago
Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
Premium
Ratings
Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
12d ago
Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating
Premium
Ratings
Positive Outlook for Nurix Therapeutics: Strong Financials and Promising Clinical Progress Support Buy Rating
12d ago
NRIX Earnings this Week: How Will it Perform?
PremiumPre-EarningsNRIX Earnings this Week: How Will it Perform?
14d ago
Nurix announces EMA grant of Orphan Drug Designation for bexobrutideg
Premium
The Fly
Nurix announces EMA grant of Orphan Drug Designation for bexobrutideg
15d ago
Promising Clinical Data from Nurix Therapeutics’ BTK Degrader NX-5948 Supports Buy Rating
Premium
Ratings
Promising Clinical Data from Nurix Therapeutics’ BTK Degrader NX-5948 Supports Buy Rating
21d ago
Optimistic Outlook on Nurix Therapeutics: Strategic Partnerships and Financial Gains Drive Buy Rating
PremiumRatingsOptimistic Outlook on Nurix Therapeutics: Strategic Partnerships and Financial Gains Drive Buy Rating
2M ago
Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6
Premium
The Fly
Oppenheimer bullish on Nurix as Sanofi opt-in, competitor data derisk STAT6
2M ago
Analyst Recommends ‘Buy’ for Nurix Therapeutics Amid Strong Endorsement and Promising STAT6 Program
Premium
Ratings
Analyst Recommends ‘Buy’ for Nurix Therapeutics Amid Strong Endorsement and Promising STAT6 Program
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100